{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:49:07Z","timestamp":1788817747595,"version":"build-2803163510"},"reference-count":33,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,2,3]]},"published-print":{"date-parts":[[2025,4]]},"DOI":"10.2967\/jnumed.124.268258","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:08:57Z","timestamp":1741349337000},"page":"585-591","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of [<sup>68<\/sup>Ga]Ga-Fibroblast Activation Protein Inhibitor\u201304 and [<sup>18<\/sup>F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy"],"prefix":"10.2967","volume":"66","author":[{"given":"Rongxi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingtong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"2025040211001548000_66.4.585.1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.83"},{"key":"2025040211001548000_66.4.585.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1117-6"},{"key":"2025040211001548000_66.4.585.3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.21037\/tgh.2018.11.02","article-title":"Solitary fibrous tumor","volume":"3","author":"Davanzo","year":"2018","journal-title":"Transl Gastroenterol Hepatol."},{"key":"2025040211001548000_66.4.585.4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13569-018-0095-9","article-title":"Retrospective audit of 957 consecutive 18F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma","volume":"8","author":"Macpherson","year":"2018","journal-title":"Clin Sarcoma Res."},{"key":"2025040211001548000_66.4.585.5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00259-016-3456-8","article-title":"Pretreatment tumor SUVmax predicts disease-specific and overall survival in patients with head and neck soft tissue sarcoma","volume":"44","author":"Ha","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025040211001548000_66.4.585.6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/MNM.0000000000000407","article-title":"18F-FDG PET-CT in soft tissue sarcomas: staging, restaging, and prognostic value?","volume":"37","author":"Gabriel","year":"2016","journal-title":"Nucl Med Commun."},{"key":"2025040211001548000_66.4.585.7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1053\/j.semnuclmed.2021.06.009","article-title":"PET\/CT variants and pitfalls in bone and soft tissue sarcoma","volume":"51","author":"Benz","year":"2021","journal-title":"Semin Nucl Med."},{"key":"2025040211001548000_66.4.585.8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00259-019-04553-8","article-title":"Good clinical practice recommendations for the use of PET\/CT in oncology","volume":"47","author":"Sala\u00fcn","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025040211001548000_66.4.585.9","first-page":"717","article-title":"18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis","volume":"44","author":"Ioannidis","year":"2003","journal-title":"J Nucl Med."},{"key":"2025040211001548000_66.4.585.10","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00259-020-05181-3","article-title":"68Ga-FAPI outperforms 18F-FDG PET\/CT in identifying solitary fibrous tumor","volume":"48","author":"Wang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025040211001548000_66.4.585.11","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1097\/RLU.0000000000003598","article-title":"Solitary fibrous tumors of the pleura shown on 18F-FDG and 68Ga-DOTA-FAPI-04 PET\/CT","volume":"46","author":"Zhang","year":"2021","journal-title":"Clin Nucl Med."},{"key":"2025040211001548000_66.4.585.12","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s00259-022-05700-4","article-title":"Head-to-head evaluation of [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET\/CT in recurrent soft tissue sarcoma","volume":"49","author":"Gu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025040211001548000_66.4.585.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266411"},{"key":"2025040211001548000_66.4.585.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967"},{"key":"2025040211001548000_66.4.585.15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cpet.2023.03.001","article-title":"Fibroblast activation protein inhibitor (FAPI)-PET imaging in sarcoma","volume":"18","author":"Kessler","year":"2023","journal-title":"PET Clin."},{"key":"2025040211001548000_66.4.585.16","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1007\/s00259-021-05374-4","article-title":"Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET\/CT","volume":"48","author":"Koerber","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025040211001548000_66.4.585.17","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1007\/s00259-021-05382-4","article-title":"Intense [68Ga]Ga-FAPI-04 uptake in solitary fibrous tumor\/hemangiopericytoma of the central nervous system","volume":"48","author":"Zhang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025040211001548000_66.4.585.18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/RLU.0000000000004635","article-title":"Solitary fibrous tumor of the prostate shown on FAPI PET\/CT","volume":"48","author":"Yang","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2025040211001548000_66.4.585.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267248"},{"key":"2025040211001548000_66.4.585.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06144-0"},{"key":"2025040211001548000_66.4.585.21","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","article-title":"Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond","volume":"49","author":"Li","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025040211001548000_66.4.585.22","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2025040211001548000_66.4.585.23","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/thno.68182","article-title":"Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics","volume":"12","author":"Wen","year":"2022","journal-title":"Theranostics."},{"key":"2025040211001548000_66.4.585.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262533"},{"key":"2025040211001548000_66.4.585.25","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.7150\/thno.86007","article-title":"Dual targeting PET tracer [68Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study","volume":"13","author":"Wang","year":"2023","journal-title":"Theranostics."},{"key":"2025040211001548000_66.4.585.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.01.007"},{"key":"2025040211001548000_66.4.585.27","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","article-title":"Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients","volume":"48","author":"Giesel","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025040211001548000_66.4.585.28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00259-021-05472-3","article-title":"Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond","volume":"49","author":"Qin","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025040211001548000_66.4.585.29","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2025040211001548000_66.4.585.30","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1007\/s00259-021-05273-8","article-title":"[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma","volume":"48","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025040211001548000_66.4.585.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262468"},{"key":"2025040211001548000_66.4.585.32","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4103\/ijnm.ijnm_22_23","article-title":"Ga68-FAPI imaging and Lu177-FAPI therapy in a case of metastatic solitary fibrous tumor","volume":"38","author":"Luthra","year":"2023","journal-title":"Indian J Nucl Med."},{"key":"2025040211001548000_66.4.585.33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","article-title":"Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma","volume":"52","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T18:20:12Z","timestamp":1743618012000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,1]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.2967\/jnumed.124.268258"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268258","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}